ClinicalTrials.gg
Not yet recruitingNCT07869888Updated Oct 13, 2026

A Study of QLS2401 Injection in Participants With Advanced Prostate Cancer

A Phase 1 interventional study of QLS2401 in Advanced Prostate Cancer, sponsored by Shanghai Qilu Pharmaceutical Research and Development Center LTD. Not yet recruiting. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Shanghai Qilu Pharmaceutical Research and Development Center LTD (part of Qilu Pharmaceutical Co., Ltd.) · Phase 1, Interventional, and Treatment

Updated Oct 13, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
252
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Study summary

This study is an open-label, dose-escalation and efficacy-expansion Phase I clinical trial designed to evaluate the safety, tolerability, pharmacokinetic (PK) profile, immunogenicity, and preliminary antitumor activity of QLS2401 as monotherapy in patients with advanced prostate cancer.

The Phase I trial is divided into Phase Ia and Phase Ib components. The Phase Ia component involves a dose-escalation study of QLS2401 as monotherapy; should the results from the Phase Ia study meet the predefined criteria, a Phase Ib efficacy-expansion study of QLS2401 as monotherapy will be conducted.

02

Conditions studied

  • Advanced Prostate Cancer

Browse trials for

03

In context

Prostatic Neoplasms

7,053 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

This study's planned enrollment of 252 is above the median of 60 across 5,354 interventional studies indexed under Prostatic Neoplasms.

Browse Prostatic Neoplasms studies →

Lead sponsor

Shanghai Qilu Pharmaceutical Research and Development Center LTD is the lead sponsor of 8 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Study participants enrolled voluntarily and signed an form. Male participants aged ≥18 years.
  • (ECOG) performance status score of 0-1.
  • Expected survival time of at least 3 months.
  • or cytologically confirmed prostate adenocarcinoma without evidence of neuroendocrine or small cell carcinoma features.
  • prostate cancer confirmed by imaging.
  • Belong to mCRPC.
  • Stage Ia participants with mCRPC who have failed or are intolerant to standard treatment.
  • Stage I participants with mCRPC who have failed or are intolerant to standard treatment.
  • Adequate function of major organs as defined by the protocol.
  • Agreement to use effective during the study (except for subjects who have undergone bilateral orchiectomy).
  • Prior to the first administration of the test drug, recover from all reversible adverse events (AEs) experienced during prior anticancer therapy.

Exclusion criteria

Exclusion Criteria:

  1. Patients who have previously received any of the following treatments are eligible:

    Patients who have previously received targeted therapies targeting PSMA or STEAP1; for Stage Ia and Stage Ib Cohort 1, prior treatment with PSMA-targeted radionuclide ligand therapy (RLT) is permitted.

    Patients who have previously received T-cell conjugate (TCE)-based therapies; Subjects who have received other systemic small-molecule anticancer therapy within 2 weeks prior to the first dose of the product, or macromolecular antitumor therapy within 28 days prior to the first dose of the investigational product, will be excluded, except for medications used to maintain castration status.

    Patients who have received traditional Chinese medicine for antineoplastic indications within 2 weeks prior to the first administration of the investigational drug; e) Patients currently receiving treatment with any drug known to prolong the or may precipitate torsades de pointes ventricular tachycardia, or who have received such drugs prior to the first administration without having reached the corresponding .

  2. Presence of central nervous system (CNS) , , or metastatic spinal cord compression requiring hormonal therapy (at doses exceeding the physiological substitution dose) prior to the first administration of the investigational drug;
  3. Receipt of radiotherapy involving irradiation of more than 25% of the bone marrow within 4 weeks prior to the first administration of the investigational drug; or receipt of localized radiotherapy (excluding cranial radiotherapy) within 2 weeks prior to the first administration of the investigational drug;
  4. Receipt of treatment with other investigational drugs or major surgery within 4 weeks prior to the first administration of the investigational drug (sufficient wound healing following major surgery must be clinically assessed); or planned bilateral orchiectomy during the study treatment period;
  5. History of epilepsy or occurrence of any condition that could trigger epileptic seizures within 12 months prior to the first administration of the investigational drug;
  6. Study participants with a history of psychotropic medication abuse, alcohol use disorder, or substance use disorder; or those with a documented history of neurological or psychiatric disorders that may contribute to poor treatment adherence.
  7. Has cardiovascular or cerebrovascular disease.
  8. Administer a within 4 weeks prior to the first dose of the investigational drug; or if administration of a live attenuated vaccine is anticipated during the study period.
  9. Pre-existing clinically uncontrolled third-space effusion prior to initial administration of the test drug.
  10. Previous history of hypertensive crisis or hypertensive encephalopathy.
  11. According to the investigator's judgment, the participant may pose an increased risk related to the study, potentially interfere with the interpretation of study results, or be deemed unsuitable for enrollment by the investigator.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
252 participants (estimated)

Study arms

  • Experimental
    QLS2401

    Once-Weekly administration; each 3-week period constitutes one treatment cycle (this may be adjusted based on preliminary study results)

    Drug: QLS2401

Interventions

  • DrugQLS2401

    Participants will receive QLS2401 via intravenous (IV) or subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose (MTD) (Phase Ia)

    MTD is determined based on the incidence of protocol-defined DLT during the first treatment cycle. Using the 3+3 dose-escalation design, MTD is defined as the highest dose level at which fewer than a predefined proportion of subjects experience DLT, while the next higher dose level exceeds the DLT threshold

    Time frame: From first dose of study treatment until the end of Cycle 1(each cycle is 21 days)

  2. Maximum administered dose (MAD)(Phase Ia)

    MAD is defined as follows: a) based on PK data, it is anticipated that at this dose level, the dose-exposure plateau has been reached, b) based on existing safety data, it is judged that dose escalation following this dose level will have a large safety risk or subject intolerance, or c) based on the PK-PD model, it suggested that the optimal target concentration of safety and efficacy has been explored.

    Time frame: From first dose of study treatment until the end of Cycle 1(each cycle is 21 days)

  3. Recommended phase II dose (RP2D) (Phase Ia)

    The RP2D will be comprehensively evaluated based on the safety, PK characteristics, and efficacy data from the Phase Ib study.

    Time frame: Through phase Ia completion, an average of 1 year

  4. The incidence and severity of adverse events (AE) (Phase Ia)

    Incidence and severity of adverse events (AEs) evaluated according to the NCI-CTCAE v5.0

    Time frame: Through phase Ib completion, an average of 1 year

  5. Prostate-specific antigen (PSA) 50% response (PSA50 response)

    Proportion of subjects with ≥ 50% PSA decrease

    Time frame: From Screening to confirmed progressive disease (approximately 1 year)

  6. Objective response rate (ORR) (phase Ib)

    Best response until progression, as defined by RECIST 1.1 and PCGW3

    Time frame: From Screening to confirmed progressive disease (approximately 1 year)

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Mar 2029, 28 months later.

Of 212 industry-sponsored phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 62. This study's planned 28 months is below that.

Counting every sponsor, half of 456 studies reached it within 43 months; a quarter within 23 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2026
First posted
Oct 13, 2026
StartEst.
Nov 6, 2026
Primary completionEst.
Mar 30, 2029
CompletionEst.
Mar 30, 2029
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07869888
Responsible party
Sponsor
First posted
Oct 13, 2026
Start date
Nov 6, 2026 (estimated)
Primary completion
Mar 30, 2029 (estimated)
Completion
Mar 30, 2029 (estimated)
Last update
Oct 13, 2026

Study contacts

Jinming Yu, Doctor
Contact
sdyujinming@126.com
13806406293

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion